Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Need to Legalize GL on Clinical Research Stressed by Committee Members
September 24, 2007
- Kyowa Hakko Recalls Coniel Tab due to Contamination Problem
September 24, 2007
- R&D NEWS IN BRIEF
September 24, 2007
- BUSINESS NEWS IN BRIEF
September 24, 2007
- OPINION／Secrets behind a Winning Recruitment Team
September 24, 2007
- TOPICS／Banyu Most Often Comes to Mind for its Female MRs: Nextit Survey
September 24, 2007
- FY2007 Annual Report on Health and Welfare Published
September 24, 2007
- Korosho to Enhance Quality Surveillance System for Generics
September 24, 2007
- 24.7 Million Units of Influenza Vaccines to Be Supplied for Next Season
September 24, 2007
- GENERICS NEWS IN BRIEF
September 24, 2007
- European GL on Hypertension, Coronary Artery Disease Revised
September 24, 2007
- Mr Abe's Decision to Resign Sends Out Shockwave
September 24, 2007
- Disinfection in Boiling SDS Should Be Made Obligatory to Prevent Secondary Infection of CJD
September 24, 2007
- Korosho to Encourage Innovation While Optimizing Healthcare Expenditures: Mr Erikawa
September 24, 2007
- MEDICAL DEVICE NEWS IN BRIEF
September 24, 2007
- Benefits of Research Must Be Returned to the People: Mr Toguchi
September 24, 2007
- New Sales Strategy Going Extremely Well: Mr Kashiwagi of sanofi-aventis
September 24, 2007
- Breast Cancer Will Be One of the Major Topics in Women's Health Week: Mr Nishiyama
September 24, 2007
- AltaCare Provides Int. Sales, Business Dev. Services for Pharma, Consumer Care Products
September 24, 2007
- Use e-Details to Enhance QOV: Mr Takuma of CareNet
September 17, 2007
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…